secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001104659-25-045073
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q1 EPS -$0.19; rusfertide Phase 3 positive, ASCO plenary June 1
---------------------------------------------------------------------------

- Cash $697.9M (up from $559.2M Dec 2024); net loss $11.7M (-$0.19/sh) vs income $207.3M in Q1 2024.
- Rusfertide Phase 3 VERIFY in PV met primary endpoint (p<0.0001) and all 4 key secondaries; ASCO plenary June 1, conf call June 2.
- Icotrokinra Phase 3 ICONIC-LEAD data presented at AAD and WCPD; Phase 2b ANTHEM-UC positive, full data later in 2025.
- Revenue $28.3M includes $22.8M rusfertide milestone recognition; vs $255M Q1 2024 with Takeda upfront.
- Pipeline: oral IL-17 antagonist PN-881 to enter clinic in 2025; cash runway through at least end of 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465925045073/0001104659-25-045073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465925045073/tm2514117d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-045073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer